```
line 16, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 8)--;
line 20, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 9)--;
lines 30-31, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 10)--;
lines 33-34, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 11)--;
line 17, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 12)--;
line 18, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 13)--;
line 24, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 14)--;
line 25, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 15)--;
line 32, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 17)--;
line 33, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 18)--;
line 37, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 19)--; and
line 25, delete "(SEQ ID NO: *)" and insert --(SEQ ID NO: 19)--; and
```

IN THE CLAIMS

Please amend the claims as follows:

- 1. (Amended) An isolated substantially homogeneous human mpl ligand polypeptide.
- 2. (Amended) An isolated substantially homogeneous human mpl ligand characterized in that:
 - (1) the ligand stimulates the incorporation of labeled nucleotides (3H-thymidine) into the DNA of IL-3 dependent Ba/K3 cells transfected with human mpl P;
 - (2) the ligand is stable to pH 2.5, SDS at 0.1%, and 2M urea;
 - (3) the ligand is a glycoprote(n; and
 - (4) the amino-terminal sequence of the polypeptide is [selected from the group

SPAPPACDPRLLNKLLRDDHVLHGR (SEQ ID NO: 6); and

SPAPPACDLRVLS (LRDDHVLHSRL)

SPAPPACDLRVLSKLLRDSHVLHSRL (SEQ ID NO: 2).

3. (Amended) An isolated <u>human mpl ligand</u> polypeptide comprising the amino-terminal sequence [SPAPPACDLRVLSKLLRDDHVLHSRL] <u>SRAPPACDLRVLSKLLRDSHVLHSRL</u> (SEQ ID NO: 2).

In claim 6, line 3, delete "(SEQ ID NO: *)" and insert -- (SEQ ID NO: 4)--.

